Azitra, Inc. (AZTR): Nasdaq/NYSE listing notice — Azitra obtains NYSE American plan approval; must meet $4M equity by April 2027

Azitra, Inc.

NYSE American accepted Azitra's plan to regain compliance with minimum $4M stockholders' equity requirement.
Company has until April 1, 2027 to achieve compliance; quarterly updates required.
Azitra is exploring multiple funding avenues to meet the equity standard.
If not compliant by deadline or progress insufficient, delisting proceedings may be initiated.
The notice does not affect immediate listing or trading of AZTR common stock.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Azitra, Inc. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(ii)).

Exchange: nyse american
Notice: extension granted
Deficiency: stockholders equity
Rules: 1003(a)(ii)

Exact text from the filing

December 16, 2025, Azitra, Inc. (the “Company”) received notice (the “Letter”) from the NYSE American LLC (“NYSE American”) that it had accepted the Company’s plan (the “Plan”) to regain compliance with the NYSE American’s continued listing standards regarding the minimum stockholders’ equity requirement of Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) and granted a plan period through April 1, 2027 (“Plan Period Deadline”). As previously reported, on October 1, 2025, the Company received a letter from the NYSE American stating that the Company is not in complian

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Azitra, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-028148

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.